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Osteopontin (OPN) is an important component of the extracellular matrix (ECM), which
promotes liver fibrosis and has been described as a biomarker for its severity. Previously,
we have demonstrated that Sex-determining region Y-box 9 (SOX9) is ectopically expressed
during activation of hepatic stellate cells (HSC) when it is responsible for the production
of type 1 collagen, which causes scar formation in liver fibrosis. Here, we demonstrate that
SOX9 regulates OPN. During normal development and in the mature liver, SOX9 and
OPN are coexpressed in the biliary duct. In rodent and human models of fibrosis, both
proteins were increased and colocalized to fibrotic regions in vivo and in culture-activated
HSCs. SOX9 bound a conserved upstream region of the OPN gene, and abrogation of
Sox9 in HSCs significantly decreased OPN production. Hedgehog (Hh) signaling has pre-
viously been shown to regulate OPN expression directly by glioblastoma (GLI) 1. Our
data indicate that in models of liver fibrosis, Hh signaling more likely acts through SOX9
to modulate OPN. In contrast to Gli2 and Gli3, Gli1 is sparse in HSCs and is not
increased upon activation. Furthermore, reduction of GLI2, but not GLI3, decreased the
expression of both SOX9 and OPN, whereas overexpressing SOX9 or constitutively active
GLI2 could rescue the antagonistic effects of cyclopamine on OPN expression. Conclusion:
These data reinforce SOX9, downstream of Hh signaling, as a core factor mediating the
expression of ECM components involved in liver fibrosis. Understanding the role and reg-
ulation of SOX9 during liver fibrosis will provide insight into its potential modulation as
an antifibrotic therapy or as a means of identifying potential ECM targets, similar to
OPN, as biomarkers of fibrosis. (HEPATOLOGY 2012;56:1108-1116)
F
ibrosis of the liver is characterized by excessive
extracellular matrix (ECM) deposition. One of
the major cell types responsible for this is the
hepatic stellate cell (HSC).1,2 In response to injury,
HSCs become activated into proliferative myofibro-
blasts, migrate into the surrounding parenchymal
cells, and secrete tissue-damaging ECM, the
major component of which is type 1 collagen
(COL1). In addition, the ECM contains a complex
mix of proteins that promote cell proliferation,
migration, and differentiation. One ECM compo-
nent with such roles is the matricellular glycophos-
phoprotein, osteopontin (OPN), also known as
secreted phosphoprotein 1.
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type 4; CYC, cyclopamine; DMSO, dimethyl sulfoxide; ECM, extracellular matrix; EV, empty vector; GLI, glioblastoma; HCV, hepatitis C virus; HSC, hepatic
stellate cell; hHSCs, human HSCs; Hh, Hedgehog; ICC, immunocytochemistry; IF, immunofluorescence; IHC, immunohistochemistry; mRNA, messenger RNA;
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OPN is detected in a wide range of tissues and body
fluids, with physiological roles during development
(e.g., in bone, bile duct formation, and during vascular
remodeling), immune system regulation, and wound
repair.3 However, it is also associated with pathological
processes relating to cancer and inflammation.3,4 The
ability of OPN to mediate such diverse cellular func-
tions is likely related to its extensive post-translational
modifications and ability to signal through several integ-
rin and CD44 variant receptors.3,5
OPN contributes to wound scarring in skin6 and has
been implicated in lung, kidney, and heart fibrosis.7-9 It
has previously been detected in activated HSCs, where
it is thought to mediate cell migration.10 More recently,
OPN levels have been highlighted as a potential bio-
marker of liver disease, levels correlating with the sever-
ity of disease,11-13 and has been reported to promote
the progression of fibrosis in nonalcoholic steatohepati-
tis.14 The latter study, and others,15 has demonstrated
regulation of OPN expression by Hedgehog (Hh) sig-
naling, mediated by the member of the glioblastoma
(GLI) family of transcription factors, GLI1, binding to
an upstream element of the OPN promoter.15 There
are three GLI transcription factors, with different activa-
tor and repressor forms of GLI2 and GLI3 generated
by alternative splicing of the parent transcripts.16
Previously, we have shown that the transcription fac-
tor, sex-determining region Y-box 9 (SOX9), becomes
ectopically expressed in activated HSCs, where it is re-
sponsible for COL1 production.17 During develop-
ment, SOX9 has diverse roles regulating the expression
of a number of genes encoding ECM proteins.18
SOX9 has also been associated with fibrotic patholo-
gies affecting the skin, kidney, and heart.18-23
In this present study, we show that OPN and SOX9
colocalize to biliary cells in the healthy liver and to the
same regions of fibrotic tissue. Both are markedly
increased during HSC activation, when it appears
unlikely that GLI1 regulates OPN. Instead, we demon-
strate that SOX9 lies downstream of GLI2 and is re-
sponsible for OPN expression. These data support a
role for SOX9 during the progression of liver fibrosis
as a regulator of key fibrotic ECM components, and
suggest that the manipulation of SOX9 or its down-
stream targets may be a means of developing antifi-
brotic therapies. Furthermore, the identification of
other ECM targets of SOX9 may have additional util-
ity as biomarkers of fibrotic severity in liver disease
similar to recent studies on OPN.11,12
Materials and Methods
Human Tissue and Serum Collection. Human fe-
tal material was collected under guidelines issued by
the Polkinghorne Committee, as described previ-
ously.17,24 Ethical approval was granted by the North
West Regional Ethics Committee. Freshly isolated
adult liver was purchased after resection (Invitrogen
Ltd., Warrington, UK) and processed as previously
described.17,24
Animal Models of Liver Fibrosis. Liver fibrosis was
induced by 5-week treatment of adult male Sprague-
Dawley rats with CCl4
25 or in C57Bl/6 mice fed a
methionine- and choline-deficient diet for 7 weeks.
Immortalized and Primary Cell Culture. Primary
rat hepatic stellate cells (rHSCs) were isolated as
described previously.17,25 Human LX2 cells were a gift
from Prof. Scott Friedman (Mount Sinai School of
Medicine, New York, NY).26 Primary human HSCs
(hHSCs) were isolated after liver resection (see Sup-
porting Materials and Methods) under ethical approval
from the Nottingham Research Ethics Committee,
activated in culture, and fixed for immunocytochemis-
try (ICC).17 All cells were cultured in monolayer at
5% CO2 and 37
C in Dulbecco’s modified Eagle’s me-
dium plus L-glutamine, Na-pyruvate, and antibiotics
supplemented with fetal bovine serum: 1% (low se-
rum) or 10% (high serum) for LX2 cells, as indicated,
or 16% for rHSCs and 10% for hHSCs.17 Gene
silencing was carried out transiently using short inter-
fering RNA (siRNA) (see Supporting Table 1) with
HiPerFect (LX2 cells) or Nucleofection for HSCs
(Amaxa Biosystems GmbH, Cologne, Germany), as
described previously.17 To interrogate Hh signaling,
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LX2 cells and rHSCs were treated with 5 lM of 3-
Keto-N-(aminoethyl-aminocaproyl-dihydrocinnamoyl)/
cyclopamine (CYC) (Merck Chemicals Ltd., Notting-
ham, UK) or 100 and 50 nM of smoothened agonist
(SAG; Merck Chemicals Ltd.) for LX2 cells and
HSCs, respectively. SAG treatments were performed in
serum-free conditions. Overexpression experiments
were carried out in LX2 cells. Plasmid transient trans-
fections were achieved using Transfast reagent (Prom-
ega, Madison, WI), as described previously,17 in the
presence or absence of CYC (described above). Briefly,
0.5 lg of expression plasmids (see Supporting Table 2)
containing SOX9 or myc-tagged constitutively active
GLI2 (GLI2DN)27 or active GLI3 (GLI3A-myc)28,29
were transiently transfected into LX2 cells. After 24
hours, cells were then treated with CYC or vehicle
control for an additional 24 hours and assayed for pro-
tein expression. All experiments were carried out with
the appropriate empty vector (EV) control.
Gene Expression, Protein Analysis, and Chroma-
tin Immunoprecipitation Assays. Antibodies used are
listed in Supporting Table 3. Tissue preparation, immu-
nohistochemistry (IHC), ICC, immunoblotting, and
quantification were performed as described previously.17
For quantitative reverse-transcription polymerase chain
reaction (qPCR), RNA was isolated from cells using the
RNeasy kit (Qiagen Ltd., West Sussex, UK). Comple-
mentary DNA (cDNA) was synthesized from 1 lg of
RNA with a RNA-to-cDNA kit (Applied Biosystems
Ltd., Cheshire, UK). qPCR reactions were carried out on
a StepOnePlus Real-Time PCR system (Applied Biosys-
tems Ltd) using 1 lL of cDNA, intron-spanning primers,
wherever possible (Supporting Table 4), and SYBR green
(PrimerDesign Ltd., Southampton, UK). GusB was used
as a housekeeper control for gene expression, as described
previously.30 Changes in messenger RNA (mRNA)
expression were calculated using DDCT methodology.
Chromatin immunoprecipitation (ChIP) assays were per-
formed as described previously.31,32 Further details are
described in the Supporting Materials and Methods.
Statistical Analysis. Statistical significance was deter-
mined by the two-tailed Student t test. All experiments
were carried out three times or more (n ¼ 3). For rHSCs,
experimental data arise from three different preparations
of stellate cells from different animals. Error bars in graphs
show the standard error for each experiment.
Results
Expression of SOX9 and OPN in Biliary Duct
and Liver Fibrosis in Humans and Rodents. SOX9
was detected in the round nuclei of biliary epithelial
cells in fetal and adult livers, where it demonstrated cel-
lular colocalization with OPN (Fig. 1 and Supporting
Fig. 1). Previous data have independently identified
OPN11,12,14 and SOX917 in areas of liver fibrosis in
animal models. Here, in rat and mouse models of liver
fibrosis, nuclear Sox9 localized to desmin-positive cells,
confirming its presence in HSCs (Fig. 2A). Opn local-
ized with Sox9 to spindle-shaped HSCs with elongated
nuclei in areas of fibrosis as well as to biliary cells (Fig.
2B). In vitro, Opn was barely detected in quiescent
rHSCs that lacked Sox9 (Fig. 3A,B and Supporting Fig.
2A,B). However, as reported by others,10,14 Opn expres-
sion was induced 60-fold and its protein increased as
rHSCs became activated on tissue culture plastic over 2
weeks, paralleling the induction of Sox9 and the se-
quential increase in Col1 (Fig. 3A,B). Similar results
were gained using the human cell line, LX2, an in vitro
model of stellate cells.26 In high-serum conditions,
which mimic stellate cell activation, OPN was increased
along with SOX9 (Fig. 3C-E). Final confirmation of
OPN cellular colocalization with SOX9 in both acti-
vated rHSCs and hHSCs was demonstrated in vitro
using immunofluorescence (IF). Nuclear SOX9 is
shown surrounded by OPN or a-smooth muscle actin
(a-SMA) (Fig. 4). These data led us to question
whether SOX9 was capable of regulating OPN.
Sox9 Is Responsible for Opn Expression in Acti-
vated HSCs. To determine whether Sox9 regulates
Opn expression, we abrogated Sox9 using siRNA in
Fig. 1. IHC of SOX9 and OPN in healthy liver. Consecutive 5-lm
sections of healthy liver in rat and human (at 18 weeks post-concep-
tion [wpc] and adulthood) stained for SOX9 and OPN (brown) and
counterstained with toludine blue. Note detection only in the round
nuclei (SOX9) and cytoplasm (OPN) of biliary epithelial cells. Size bar
represents 50 lm.
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activated rHSCs. Reducing Sox9 by 70%-80% caused
a commensurate 50%-70% decrease in Opn transcript
and its encoded protein (Fig. 5A,B). Similar results
were detected in the LX2 HSC line (Fig. 5C). In silico
analysis of the OPN 5’ flanking region identified a
conserved SOX9 binding motif 3 kilobase pairs
Fig. 2. IHC of SOX9, OPN, and desmin in fibrotic liver. (A) Dual IF in fibrotic tissue from rat and mouse showing nuclear Sox9 (red) in biliary
cells (asterisks) and in cells with cytoplasmic staining for desmin (green) (white arrowheads). (B) Consecutive 5-lm tissue sections shown from
fibrotic rat and mouse liver stained with Sox9 and Opn (brown) counterstained with toluidine blue. Note similarly located staining for Sox9 and
Opn in cells with more spindle-shaped nuclei (arrows) as well as in biliary cells (asterisk). Size bars represent 100 lm.
Fig. 3. SOX9 and OPN expression in activated HSCs. (A-E) Quantification of SOX9 and OPN in quiescent and activated rHSCs and LX2 cells
by qPCR (A and C) and immunoblotting (B, D, and E) (in [A], Sox9 was up-regulated 8.0-fold). In (B), induction of Sox9, Opn, and Col1 is
shown during activation of rHSCs in culture (relative to quiescent; day 0). Representative immunoblotting images for (B) and (D) are shown as
inset (B) or as an individual image (E), respectively. All immunoblotting quantification was normalized to b-actin. *P < 0.05; †P < 0.005, com-
pared to quiescent day 0 cells (A and B) or 0% serum (C and D).
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upstream of the transcriptional start site (Fig. 5D).
ChIP demonstrated that Sox9 was enriched at this site
in both activated rHSCs and human LX2 cells
(Fig. 5E; negative control data for GAPDH shown in
Supporting Fig. 3). These data indicate that OPN is a
novel downstream target of SOX9. Because others
have implicated the Hh pathway in liver fibrosis33 and
as a regulator of OPN expression,14,15 and because in
Fig. 4. SOX9 and OPN expression in acti-
vated hHSCs and rHSCs. IF showing nuclear
SOX9 (red) and cytoplasmic a-SMA (green;
left panel) or OPN (green; right panel) in rat
and human activated HSCs (aHSCs). Size bar
represents 20 lm.
Fig. 5. SOX9 regulation of OPN in HSCs. (A-C) siRNA abrogation of Sox9 in activated rHSCs (A and B) and LX2 cells (C) standardized against
scrambled siRNA control for mRNA (A) and protein (B and C). Example immunoblotting is shown as inset in (B) and (C). *p < 0.05; **P <
0.01; †P < 0.005; ‡P < 0.001, compared to control. (D) Alignment of the upstream OPN enhancer region with conserved SOX9-binding motif
highlighted in black (human sequence shown is 3,886 to 3,842 base pairs relative to transcriptional start site). Conserved nucleotides indi-
cated by asterisk (*). The core SOX-binding motif is CAAT with increased binding affinity for SOX9 conferred by additional flanking nucleotides.49
(E) ChIP assay for SOX9-binding element in conserved upstream OPN enhancer element in LX2 cells cultured in high serum and activated rHSCs.
Negative control is immunoglobulin G (IgG), and positive control is input (diluted 10-fold).
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different circumstances SOX9 has been reported down-
stream of Hh signaling,18 we were curious to investi-
gate whether SOX9 might be regulated by Hh in stel-
late cells as a means of determining OPN production.
Hh Signaling Regulates SOX9 and Its Down-
stream Target, OPN. Serum-activated LX2 cells and
rHSCs activated in culture for 10 days were incubated
with the Hh antagonist, CYC, or agonist, SAG (Fig.
6A-D and Supporting Fig. 4A,B). Both SOX9 and
OPN proteins were significantly decreased by 45%-
60% in response to CYC and increased 2- to 3-fold
after SAG treatment in both stellate cell models. These
data demonstrate that both OPN and SOX9 are posi-
tively regulated by Hh signaling in stellate cells. To
intimate a role for SOX9 as the mediator of Hh’s
effect on OPN production, we used siRNA in LX2
cells after SAG augmentation of Hh signaling (Fig. 6E
and Supporting Fig. 4C). SAG induced increases in
both SOX9 and OPN protein, compared to dimethyl
sulfoxide (DMSO) control, which were unaffected by
control siRNA. However, siRNA abrogation of SOX9
prevented the Hh agonist from increasing OPN levels
above DMSO control values. To perform the converse
experiment, transient transfection of an expression vec-
tor containing the human SOX9 coding sequence was
carried out to overexpress SOX9 in LX2 cells (Support-
ing Fig. 4D). Overexpression of SOX9 rescued the in-
hibitory effect of CYC on OPN production (Fig. 6F).
Collectively, these data implicate SOX9 as a positive
regulator of OPN production downstream of Hh sig-
naling in stellate cells.
The Hh Mediator, GLI2, Regulates SOX9 Expres-
sion. The GLI family of transcription factors is known
to mediate the effects of Hh signaling.16 To determine
which GLI factor might be responsible for Hh’s effect
on SOX9 expression, we first investigated the expres-
sion of family members in quiescent and activated
rHSCs. By qPCR, Gli1 was poorly detected in quies-
cent HSCs and unaltered upon activation (Fig. 7A).
In contrast, Gli2 and Gli3 mRNAs were increased
Fig. 6. Hh regulates SOX9 and OPN expression in HSCs. (A-D) SOX9 and OPN protein levels quantified from immunoblotting of activated
rHSCs and LX2 cells after 24-hour treatment with the Hh antagonist, CYC, or the Hh agonist, SAG. (E) Protein levels for SOX9 and OPN after
treatment with SAG for 24 hours and knockdown of SOX9 (by 87%) using siRNA or scrambled control in LX2 cells. (F) Quantification of OPN pro-
tein after overexpression of SOX9 in LX2 cells in the presence or absence of CYC. Example immunoblotting image shown in inset. Change in
expression is compared to vehicle treated cells (DMSO) for all experiments and, in the case of (F), EV control. Experiments standardized against
b-actin. *P < 0.05; **P < 0.01; †P < 0.005; ‡P < 0.001, compared to control.
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6- and 50-fold, respectively, in activated cells.
Although, by this analysis, GLI3 appears the more likely
candidate for the regulation of SOX9 in stellate cells,
detection of mRNA is not indicative of protein levels,
especially given the potential for both repressor or acti-
vator forms of GLI2 and GLI3. Several commercial and
published antibodies were available to us29,34,35; how-
ever, we found them unhelpful in detecting or distin-
guishing the different forms by immunoblotting. There-
fore, we investigated the potential contribution of GLI2
and GLI3 to SOX9 and OPN expression by using
siRNA in LX2 cells (Fig. 7B,C). Diminution of GLI2
transcripts by 67% significantly reduced SOX9 and
OPN expression by 43% and 64%, respectively
(Fig. 7B). In comparison, although achieving more ro-
bust reduction in GLI3 expression (86%) with
siRNA, SOX9 expression was less affected and OPN
was unaltered (Fig. 7C). Moreover, overexpression of
constitutively active GLI2 (GLI2DN) was able to res-
cue, at least partially, the antagonistic effects of CYC on
SOX9 and OPN production (Fig. 8A,B and Supporting
Fig. 5A). In contrast, overexpressing the activator form
of GLI3 (GLI3A) in the presence of CYC had little or
no positive effect on SOX9 or OPN production (Fig.
8C,D and Supporting Fig. 5B). These data imply that
GLI2 is the predominant regulator of SOX9 expression
in HSCs. In keeping with these results, nuclear immu-
noreactivity against Gli2 was detected in activated
rHSCs in vitro and in regions of fibrosis after CCl4
treatment in vivo (Fig. 8E). Interestingly, Gli2 was also
detected in the round nuclei of biliary epithelial cells
similar to Sox9 and Opn (Fig. 8E, arrows). In contrast,
despite detecting nuclear immunoreactivity for Gli3 in
control brain tissue during human fetal development,
such staining was not apparent in fibrotic rat tissue
(data not shown).
Fig. 7. Gli2 mediates the expression of Sox9 and Opn in HSCs. (A) Expression of Gli factors in quiescent and activated rHSCs by qPCR. (B
and C) siRNA for GLI2 (B, 67% knockdown) and GLI3 (C, 86% knockdown) or scrambled control in LX2 cells, followed by qPCR for GLI2 (B) or
GLI3 (C), SOX9, and OPN. *P < 0.05; †P < 0.005; ‡P < 0.001, compared to scrambled siRNA treatment.
Fig. 8. Gli2 overexpression rescues antagonistic effects of CYC on
the expression of Sox9 and Opn in HSCs. (A-D) Quantification of
SOX9 and OPN protein after overexpression of constitutively active
GLI2 (GLI2DN; A and B) or active GLI3 (GLI3A; C and D) in LX2 cells
in the presence or absence of CYC. (E) IF showing nuclear Gli2 (red)
and cytoplasmic a-Sma (green) in activated rHSCs (aHSCs) and
bright-field IHC showing nuclear Gli2 (brown staining) in CCl4-treated
fibrotic rat liver. Arrows indicate Gli2 expression in a bile duct. *P <
0.05; **P < 0.01; †P < 0.005, ‡P < 0.001, compared to EV trans-
fection. Size bar represents 20 lm.
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Discussion
OPN has been implicated as an important mediator,
by which the inflammatory response ultimately leads to
scarring and fibrosis in various organs,6-10,14 with the
potential that its presence in the circulation can be used as
a biomarker of disease progression.11-13 Previously, we
demonstrated a novel role for the transcription factor,
SOX9, in models of liver fibrosis. Under the influence of
transforming growth factor-beta (TGF-b) signaling,
SOX9 became expressed in activated HSCs, where it was
responsible for the production of the profibrotic collagen,
COL1.17 In this study, we have demonstrated a more
diverse role for SOX9 by regulating OPN expression. In
the liver, SOX9 and OPN colocalized in the regions of fi-
brosis. The onset of OPN production during rHSC acti-
vation, its reduction in activated HSCs after Sox9 abroga-
tion, and the binding of SOX9 to an upstream OPN
enhancer element infers that the transcription factor is
required for OPN expression during liver fibrosis.
SOX9 was responsive to Hh signaling in our models
of liver fibrosis. Although Hh’s precise role in vivo dur-
ing liver fibrosis remains incompletely understood,36,37
the signaling pathway is reactivated after injury in
adult tissues38 and HSCs can produce and respond to
Hh ligands.30,39 Several lines of evidence place SOX9
downstream of Hh signaling. SOX9 is up-regulated by
Hh ligands during chondrogenesis and, in neural stem
cells, skin and intestine.18 The GLI family of zinc-fin-
ger transcription factors mediates Hh signaling in
mammals.16 GLI1 is generally thought to be a tran-
scriptional activator, whereas GLI2 and GLI3 have
additional potential N-terminal repressor functions af-
ter proteolytic cleavage. There are several conserved
GLI-binding motifs important for SOX9 expression in
its extended 5’ flanking region (up to 1.1 Mb).18,40
Whereas Gli1 seems important for Sox9 expression
during chondrogenesis41 and for a SOX9-independent
effect on OPN expression in malignant melanoma,15
the transcription factor was poorly detected in our
models of liver fibrosis. In contrast, Gli2 increased
Sox9 during mouse pancreatic b-cell dedifferentia-
tion.42 Here, we demonstrate a role for GLI2 in regu-
lating SOX9 and OPN in models of liver fibrosis. This
is in line with the detection of hepatic Gli2 by
others.33 However, compared to a direct effect of
GLI2 on OPN, our collective data indicate that GLI2
functions significantly through SOX9 in its regulation
of OPN production. This mechanism may also extend
to the up-regulation of SOX9 by TGF-b, because
GLI2 is induced by TGF-b in several cell types,
including fibroblasts, keratinocytes, and cancer cells.43
In the healthy liver, both SOX9 and OPN localize
to the bile ducts. SOX9 is required for normal biliary
formation and function.44,45 From our data, it seems
likely that SOX9 would also be responsible for OPN
production by healthy cholangiocytes. Furthermore,
based on SOX9’s additional roles in regulating both
COL117 and collagen type 4 (COL4),23 there is the
potential that SOX9 could be important in chronic
cholestatic liver injury by regulating all these ECM
components as part of the pathology of primary biliary
cirrhosis (PBC) and primary sclerosing cholangitis.
Interestingly, TGF-b and Hh signaling (including
Gli2), both of which would up-regulate SOX9, have
been implicated in the fibrotic response of PBC,46,47
where COL1, COL4, and OPN are all increased.48
In summary, these data expand the role for SOX9
in regulating components of the ECM and begin to
provide insight into its regulation by signaling path-
ways linked to fibrosis and related pathologies in the
liver and other sites, such as the skin, kidney, lung,
and major blood vessels.18 Finally, given the potential
use of serum OPN as a biomarker for the severity of
liver damage in patients with HBV or HCV,11,12 it is
possible that additional downstream ECM targets of
SOX9 action may be useful in helping to stage and
predict the severity of liver fibrosis.
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